What are the outcomes for long-term survivors after esophagectomy ? – Evidence from a randomized controlled trial (FFCD9901)
Being alive 5 years after esophagectomy does not equate to cure. In clinically staged early disease, a distinct group of patients develop disease recurrence later than 5 years from treatment. Development of a second primary cancer in this population poses a clinical threat. Surveillance protocols should be adapted accordingly.
Authors
- Laëtitia Dahan (ORCID: https://orcid.org/0000-0001-5267-6190)
- Marine Jary (ORCID: https://orcid.org/0000-0001-7502-7708)
- Niki Christou (ORCID: https://orcid.org/0000-0003-2125-0503)
- Guillaume Piessen (ORCID: https://orcid.org/0000-0001-8243-8310)
- Julie Véziant (ORCID: https://orcid.org/0000-0001-5247-461X)
- F. Mornex (ORCID: https://orcid.org/0000-0002-0234-1269)
- Sylvain Manfrédi (ORCID: https://orcid.org/0000-0001-7530-4621)
- Côme Lepage (ORCID: https://orcid.org/0000-0001-9211-4707)
- Valérie Boige (ORCID: https://orcid.org/0000-0002-7817-4663)
- Xavier Benoît D’Journo (ORCID: https://orcid.org/0000-0001-6747-4583)
- Emilie Barbier
- William B. Robb
Institutions
- Centre National de la Recherche Scientifique (FR)
- Royal College of Surgeons in Ireland (IE)
- Inserm (FR)
- Université de Bourgogne (FR)
- Aix-Marseille Université (FR)
- Université de Lille (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Hôpital Lyon Sud (FR)
- Hôpital Nord (FR)
- Centre Hospitalier de Saint-Malo (FR)
- Fédération Francophone de Cancérologie Digestive (FR)
- Int'Air Medical (France) (FR)
- Maison des Sciences sociales et des Humanités de Dijon (FR)
- AlterSanté (FR)
- Université d'été de Boulogne-sur-Mer (FR)
- Onco Lille (FR)
- Université de Limoges (FR)
Publication Details
- Journal
- European Journal of Surgical Oncology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1016/j.ejso.2025.109736
- Citations
- 4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.03
Funders
- Centre hospitalier régional universitaire de Lille
- National Cancer Institute